Eur Urol. 1976;2(3):138-41. doi: 10.1159/000471984.
Single-drug chemotherapy was employed in a multicentric co-operative trial. Adriamycin was given to 18 patients, VM-26 to 30 and Bleomycin to 33. Almost all patients were suffering from a T3 or T4 bladder cancer with known metastases in almost 40% of cases. The vast majority of patients had already received previous treatment either chemotherapy, surgery of irradiation. Complete regression was obtained in 5% of cases; partial objective regression in 11.1% of patients treated with Adriamycin, 26.6% with VM-26 and 33.3% with Bleomycin. The results were uniformly better when high dosages of drug were employed. No clear-cut superiority of one drug over the others can be demonstrated.
在一项多中心合作试验中采用了单药化疗。对18例患者给予阿霉素，30例给予威猛（VM - 26），33例给予博来霉素。几乎所有患者都患有T3或T4期膀胱癌，近40%的病例已有已知转移。绝大多数患者此前已经接受过化疗、手术或放疗。5%的病例获得完全缓解；接受阿霉素治疗的患者中11.1%部分客观缓解，接受威猛治疗的为26.6%，接受博来霉素治疗的为33.3%。使用高剂量药物时结果普遍更好。无法证明一种药物明显优于其他药物。
